SBI, Theragnostics ink oral cancer technology deal

By DrBicuspid Staff

September 23, 2020 -- Molecular radiotherapy developer Theragnostics and Summit Biomedical Imaging (SBI) have signed a licensing agreement to support the development of SBI's oral cancer detection technology.

The technology is intended to provide earlier diagnosis of cancer using the poly (ADP-ribose) polymerase (PARP) inhibitor PARPi-FL and fluorescence imaging in the oral cavity.

PARP activity and expression are upregulated in tumor cells. The inhibitor binds to PARP with a fluorescence tag, bringing the optical imaging agent to the cancer and enabling direct tumor detection, according to the companies.

Copyright © 2020

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking